White papers and other resources

Scientific journals

Conference posters

September 21, 2023
5th Annual RAS-Targeted Drug Development Summit 2023
ResponderID™ KRAS: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapeutics
June 13, 2023
EACR 2023
Evaluation of a KRAS gene expression signature in lung cancer
April 17, 2023
AACR 2023
The Xerna™ TME Panel potentially predicts response to a combination of the TLR9 agonist vidutolimod and PD-1 inhibitor pembrolizumab in metastatic melanomas with prior anti-PD-1 treatment
April 5, 2023
HubXchange 2023
ResponderID™: The Biology-First Machine Learning Platform for Biomarker Discovery
November 30, 2022
SITC 2022
Xerna tumor microenvironment subtypes as a biomarker in lung cancer patients
September 30, 2022
ESMO 2022
Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA assay
April 11, 2022
AACR 2022
Xerna™ TME Panel: A pan-cancer RNA-based investigational assay designed to predict patient response to angiogenic- and immune-targeted therapies
April 12, 2021
AACR 2021
RNA-Based Diagnostic Panel Matches TME Phenotype to Therapeutic Mechanism of Action in Colorectal Cancer

Genialis Highlights Power of its Supermodel to Predict and Explain Therapeutic Response at AACR 2025. Read the press release →

Genialis Highlights Power of its Supermodel to Predict and Explain Therapeutic Response at AACR 2025. Read the press release → Genialis Highlights Power of its Supermodel to Predict and Explain Therapeutic Response at AACR 2025. Read the press release →

This website uses cookies and third party services. Read More Accept Reject